Plain-English translation of NCT07226206 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hemophilia A research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called for adults with severe hemophilia A. Hemophilia A is a genetic disorder where your blood cannot clot normally, leading to excessive bleeding. The study will evaluate how safe and well-tolerated this medication is in a small group of adult men.
Current hemophilia A treatments require frequent infusions to replace the missing clotting factor, which can be burdensome and still don't fully prevent bleeding episodes. This medication is being explored as a potential one-time or long-lasting solution that might reduce or eliminate the need for regular treatment infusions.
You likely qualify if…
You likely don't qualify if…
You will receive a single intravenous infusion of the medication on Day 1 of the study. The trial will then follow you closely over time with blood tests, physical exams, and visits to monitor how your body responds and to track any side effects. The study team will assess your bleeding episodes and how well the treatment works for you.
AI-generated summary from trial data · Jul 2, 2026 · Not medical advice
United States